Data favor Merck, Eisai’s Keytruda-Lenvima as the winner in kidney cancer, but window still open for Bristol Myers



The immuno-oncology data showdown between team Merck and team Bristol Myers Squibb in kidney cancer appears to have a winner in the eyes of at least one analyst. But that doesn’t mean the other party has lost the fight.
After last week’s American Society of Clinical Oncology’s Genitourinary Cancers Symposium, Merck and Eisai’s Keytruda-Lenvima combo is the “clear choice” to elicit a rapid, durable response in most patients with previously untreated renal cell carcinoma, SVB Leerink analyst Daina Graybosch said in a Tuesday note.
It’s a hard-fought win, with challengers including Keytruda’s pairing with Pfizer's tyrosine kinase inhibitor (TKI) Inlyta, Bristol Myers’ dual immunotherapy Opdivo and Yervoy, as well as Opdivo’s TKI combo with Exelixis’ Cabometyx. Graybosch reached the conclusion based on separate trials pitting those regimens against Pfizer’s standard treatment Sutent.

In the Keynote-581 study, the Keytruda-Lenvima therapy triggered a response in 71% of patients, clearly higher than the 60% posted by Keytruda-Inlyta in its own Keynote-426 trial, which earned second place among the four regimens in terms of overall response rate.

So far, at roughly two years of follow-up, the four combos have exhibited very similar abilities to help patients live longer, having pared down the risk of death by 32% to 34% across their own trials. But Graybosch pointed to Keytruda and Lenvima’s best-in-class performance on complete tumor clearance and best duration of response among I-O/TKI options as “early signals” of a strong overall survival.

After talking to two industry experts, Graybosch identified two additional chance for Merck to win over the market with “effective commercial and medical execution.”

First off, Graybosch’s interpretation that Keytruda-Lenvima holds the best potential for longer overall survival was not shared by both the experts she consulted. But Graybosch argued that the fact the theory received some support leaves room for the combo—and I-O/TKIs in general—to cut into the roughly 38% market share held by Opdivo and Yervoy in front-line kidney cancer.

While one expert expressed confidence in the Yervoy regimen and preferred to use it upfront for low- and intermediate-risk patients, the other expert said physicians simply like the I-O duo because of its first-to-market advantage.

At ASCO GU, Bristol Myers and Exelixis also pointed up health-related quality of life benefits for the Opdivo-Cabometyx combo from the CheckMate-9ER trial. The combo is also linked to fewer side effect events and lower treatment discontinuation rates compared with the two Keytruda combos in their respective trials.

But the two experts argued that comparing these data across trials may be misleading because Keynote-581 started with a higher dose of Lenvima than what doctors usually use, while CheckMate-9ER started with a lower-than-typical dose for Cabometyx. Plus, despite a higher discontinuation rate, Keytruda enjoyed a median duration of treatment about a month longer than Opdivo's in these two trials, Graybosch noted.
The experts think the real-world I-O/TKI tolerability will be similar, saying that “ultimately, patients will gravitate to a dose tolerable for them,” according to Graybosch.

Does that mean the Keytruda-Lenvima holds a clear and safe leading spot in front-line kidney cancer? Not necessarily, Graybosch said, pointing to three uncertainties that could shift the market down the line.

First, the SVB Leerink analyst said she’s still waiting for more risk subgroup data, which could eventually divide the market. She also questioned whether doctors might save the better TKIs for later lines of therapy.

The next wave of combinations could pose a bigger threat. One of the experts was excited about Bristol’s Opdivo-Yervoy-Cabometyx triplet now under study in the COSMIC-313 trial; that test bears a primary end date in November. Bristol Myers also has a partnership with Nektar Therapeutics on IL-2 drug bempegaldesleukin, which it's exploring alongside Opdivo across different types of cancer, including kidney cancer, with data expected soon.

Source:https://www.fiercepharma.com/marketing/data-favor-merck-eisai-s-keytruda-lenvima-as-winner-kidney-cancer-but-window-still-open

Comments

Post a Comment

Popular posts from this blog

EMA validates Incyte’s MAA for retifanlimab to treat metastatic squamous cell anal carcinoma

Incyte, global biopharmaceutical company, announced the validation of the Company’s Marketing Authorization Application (MAA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell anal carcinoma (SCAC) who have progressed on, or who are intolerant of, platinum-based chemotherapy. The European Medicines Agency’s (EMA) validation of the MAA confirms that the submission is sufficiently complete to begin the formal review process. “While the incidence of SCAC is increasing in Europe, treatment options for advanced disease are limited in their effectiveness, and there are no approved options once patients have progressed on standard therapy,” said Lance Leopold, M.D., Group vice president, Immuno-Oncology Clinical Development, Incyte. “The EMA validation of the MAA for retifanlimab – which follows the recent US Food & Drug Administration acceptance of our Biologics License Application for Priority R...
Read more

Tumour-targeting drug paves way for bone cancer treatment

 The treatment of osteosarcoma, the most common tumour of bone, is challenging, but a new study is offering hope to the patients with this disease. The study led by The University of  Texas MD Anderson Cancer Centre  found that a drug, known as bone metastasis-targeting peptidomimetic (BMTP-11), has potential as a new therapeutic strategy for this devastating illness. Results from the preclinical study looked at BMTP-11 alone and in combination with the chemotherapy agent gemcitabine. Although osteosarcoma is a relatively rare cancer, it is a leading disease-related cause of death in children and young adults ages 10 to 20. However, over the last 25 years, the five-year survival rate has remained unchanged, and the treatment options for these patients are few. In addition, the side effects of available treatment options often are significant and cumulative, and may cause other health problems and damage to major organs. "What's novel about this treatment is that...
Read more

Merck’s Keytruda plus platinum- and fluoropyrimidine-based chemotherapy receives US FDA nod to treat certain patients with locally advanced/metastatic esophageal or GEJ carcinoma

Merck, known as MSD outside the United States and Canada, announced that the US Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation in combination with platinum- and fluoropyrimidine-based chemotherapy. The approval is based on results from the phase 3 KEYNOTE-590 trial, which demonstrated significant improvements in overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) for Keytruda plus fluorouracil (FU) and cisplatin versus FU and cisplatin alone, regardless of histology or PD-L1 expression status. For OS and PFS, Keytruda plus FU and cisplatin reduced the risk of death by 27% (HR=0.73 [95% CI, 0.62-0.86]; p<0.0001) and reduced the risk of disease progression or death...
Read more